Stock listing
NASDAQ:DMRA Damora Therapeutics, Inc. Stock
Home listing (NASDAQ) of Damora Therapeutics, Inc.
Follow Damora Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:DMRA
$23.22 USD +0.24 (+1.0%)
Close on Nov 20, 2026
- Day range
- $23.13 – $24.51 USDNov 20, 2026
- Volume
- 643,377 sharesNov 20, 2026
- Market cap
- $1.44B USDAt the close on Nov 20, 2026 · price × 61.90M shares outstanding
- 52-week range
- $15.76 – $38.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.12M USDMedian day 473,165 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DMRA · Home | $23.22 USD | +0.24 (+1.0%) | 643,377 | $23.81 | $24.51 | $23.13 | $22.98 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DMRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $23.22 | +0.24 | +1.0% | $23.81 | $24.51 | $23.13 | 643,377 | |
| $22.98 | +0.42 | +1.9% | $22.54 | $23.61 | $22.08 | 580,492 | |
| $22.56 | +0.065 | +0.3% | $22.65 | $22.75 | $21.89 | 395,993 | |
| $22.50 | +0.895 | +4.1% | $21.88 | $23.75 | $21.33 | 1,232,435 | |
| $21.60 | -0.45 | -2.0% | $22.11 | $22.38 | $21.15 | 475,265 | |
| $22.05 | -1.20 | -5.2% | $23.04 | $23.04 | $21.83 | 671,091 | |
| $23.25 | -0.90 | -3.7% | $24.15 | $25.07 | $23.20 | 535,858 | |
| $24.15 | +0.08 | +0.3% | $23.75 | $24.76 | $23.45 | 466,095 | |
| $24.07 | +0.37 | +1.6% | $24.01 | $24.94 | $23.34 | 564,142 | |
| $23.70 | +1.84 | +8.4% | $22.01 | $24.16 | $21.13 | 360,452 | |
| $21.86 | -1.08 | -4.7% | $23.15 | $24.80 | $20.75 | 792,593 | |
| $22.94 | +0.86 | +3.9% | $23.37 | $23.40 | $21.45 | 736,739 | |
| $22.08 | +0.48 | +2.2% | $21.76 | $22.77 | $21.70 | 473,165 | |
| $21.60 | +0.11 | +0.5% | $21.75 | $21.94 | $20.75 | 497,323 | |
| $21.49 | -0.52 | -2.4% | $21.95 | $22.20 | $21.05 | 339,515 | |
| $22.01 | +0.40 | +1.9% | $22.06 | $23.21 | $21.50 | 460,310 | |
| $21.61 | -0.35 | -1.6% | $21.93 | $22.51 | $20.46 | 341,763 | |
| $21.96 | +0.70 | +3.3% | $21.26 | $22.27 | $20.23 | 286,092 | |
| $21.26 | +0.17 | +0.8% | $21.19 | $21.78 | $21.09 | 641,718 | |
| $21.09 | -0.62 | -2.9% | $21.40 | $21.53 | $20.46 | 359,783 | |
| $21.71 | +0.18 | +0.8% | $21.45 | $21.88 | $20.92 | 420,641 | |
| $21.53 | +0.86 | +4.2% | $20.88 | $22.68 | $20.66 | 683,090 | |
| $20.67 | +1.40 | +7.3% | $19.30 | $20.92 | $19.30 | 242,321 | |
| $19.27 | +0.83 | +4.5% | $18.56 | $19.94 | $18.52 | 293,164 | |
| $18.44 | -0.30 | -1.6% | $18.69 | $18.80 | $17.49 | 836,700 | |
| $18.74 | +0.31 | +1.7% | $18.59 | $18.89 | $17.84 | 357,600 | |
| $18.43 | -0.13 | -0.7% | $18.21 | $18.98 | $18.00 | 277,600 | |
| $18.56 | -1.695 | -8.4% | $20.09 | $20.28 | $18.50 | 285,200 | |
| $20.26 | -0.825 | -3.9% | $20.93 | $21.26 | $20.05 | 267,900 | |
| $21.08 | +0.52 | +2.5% | $20.53 | $21.86 | $20.44 | 368,700 | |
| $20.56 | +0.32 | +1.6% | $19.96 | $20.87 | $19.22 | 341,800 | |
| $20.24 | +0.69 | +3.5% | $19.36 | $20.35 | $18.69 | 488,800 | |
| $19.55 | -0.67 | -3.3% | $20.42 | $20.48 | $18.20 | 1,171,600 | |
| $20.22 | -0.43 | -2.1% | $20.64 | $20.70 | $19.54 | 556,100 | |
| $20.65 | +0.42 | +2.1% | $20.55 | $20.77 | $19.59 | 692,900 | |
| $20.23 | -1.05 | -4.9% | $20.51 | $21.25 | $20.20 | 354,600 | |
| $21.28 | +0.62 | +3.0% | $20.78 | $21.85 | $20.31 | 563,000 | |
| $20.66 | -0.09 | -0.4% | $20.67 | $20.82 | $20.16 | 376,400 | |
| $20.75 | +0.09 | +0.4% | $21.26 | $21.59 | $19.83 | 514,900 | |
| $20.66 | +0.39 | +1.9% | $20.80 | $20.80 | $19.80 | 1,431,800 | |
| $20.27 | -0.17 | -0.8% | $20.38 | $20.73 | $19.39 | 875,200 | |
| $20.44 | -1.97 | -8.8% | $22.12 | $22.12 | $19.96 | 1,067,200 | |
| $22.41 | -0.44 | -1.9% | $23.21 | $23.43 | $21.95 | 355,200 | |
| $22.85 | +0.26 | +1.2% | $22.80 | $23.33 | $22.01 | 618,200 | |
| $22.59 | -0.19 | -0.8% | $22.94 | $23.44 | $22.02 | 3,316,800 | |
| $22.78 | -1.75 | -7.1% | $24.96 | $25.49 | $22.74 | 605,100 | |
| $24.53 | -0.22 | -0.9% | $24.88 | $25.27 | $23.91 | 1,241,800 | |
| $24.75 | -3.64 | -12.8% | $28.00 | $28.17 | $24.14 | 1,677,900 | |
| $28.39 | +0.29 | +1.0% | $28.42 | $29.18 | $28.00 | 372,100 | |
| $28.10 | +1.26 | +4.7% | $27.32 | $28.53 | $26.87 | 525,400 | |
| $26.84 | +0.57 | +2.2% | $25.87 | $27.78 | $25.63 | 639,800 | |
| $26.27 | -2.90 | -9.9% | $28.77 | $29.29 | $26.26 | 500,100 | |
| $29.17 | -0.89 | -3.0% | $29.66 | $30.74 | $28.89 | 560,000 | |
| $30.06 | +2.06 | +7.4% | $27.49 | $30.35 | $27.39 | 295,800 | |
| $28.00 | -0.18 | -0.6% | $28.52 | $28.60 | $27.40 | 328,200 | |
| $28.18 | +0.04 | +0.1% | $28.36 | $29.38 | $27.82 | 462,900 | |
| $28.14 | -0.04 | -0.1% | $28.10 | $28.45 | $27.12 | 272,700 | |
| $28.18 | -0.82 | -2.8% | $28.93 | $28.93 | $26.53 | 497,000 | |
| $29.00 | -1.60 | -5.2% | $30.38 | $30.71 | $28.42 | 371,700 | |
| $30.60 | +0.21 | +0.7% | $30.18 | $31.11 | $29.87 | 171,300 | |
| $30.39 | -0.23 | -0.8% | $30.48 | $30.88 | $30.10 | 185,900 | |
| $30.62 | +0.31 | +1.0% | $30.55 | $31.64 | $30.54 | 205,709 | |
| $30.31 | -0.51 | -1.7% | $30.67 | $31.49 | $29.70 | 319,817 | |
| $30.82 | +0.51 | +1.7% | $30.45 | $31.38 | $30.15 | 159,900 | |
| $30.31 | -2.13 | -6.6% | $31.84 | $32.07 | $30.12 | 226,500 |
Splits
1 split · NASDAQ:DMRA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:DMRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 23 slides
Latest news
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026
Closed $23.70 (+8.4%) on Nov 6, 2026
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Nov 4, 2026
Closed $21.86 (-4.7%) on Nov 5, 2026
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
Nov 4, 2026
Closed $22.94 (+3.9%) on Nov 4, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
Oct 5, 2026
Closed $20.22 (-2.1%) on Oct 5, 2026
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Aug 10, 2026
Closed $30.36 (+2.8%) on Aug 11, 2026
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
Aug 5, 2026
Closed $30.83 (+2.7%) on Aug 5, 2026
Damora Announces Redomestication from Delaware to Cayman Islands
Jul 17, 2026
Closed $31.48 (+4.1%) on Jul 17, 2026
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026
Closed $24.16 (+4.6%) on May 13, 2026
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Mar 23, 2026
Closed $23.05 (+27.1%) on Mar 23, 2026
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Mar 19, 2026
Closed $18.14 (-5.5%) on Mar 20, 2026
Damora Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 13 in all · newest Nov 5, 2026 · oldest 2026
- Decks
- 2 decks · latest August 2026
Where Damora Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DMRA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:DMRA | BOATS | United States | USD |
Valuation
Price/book 2.9× against a median of 2.5×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $910.0M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.88
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Alvotech · NASDAQ:ALVO | US$1.47B | US$2.78B | n/a | 5.7× | 31.4× | n/a | −36.5% | n/a | 0.90 |
| ABL Bio, Inc. · KRX:298380 | US$1.47B | US$1.34B | n/a | 52.7× | n/a | 11.5× | −229.4% | 0.0× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.6× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.42B | US$1.14B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Median of the others | US$1.44B | US$1.37B | 34.1× | 31.4× | 2.5× | −121.0% | 0.1× | 1.49 |
Forecasts
9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 46.78 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.89 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jennifer Jarrett | President and Chief Executive Officer in March 2026, Board Director |
| Brian Burkavage | Senior Vice President, Finance |
| Sherwin Sattarzadeh | Chief Operating Officer |
| Garrett Winslow | General Counsel |
| Becker Hewes | Chief Medical Officer |
| Jim Baker | Chief Corporate Affairs Officer |
Board
| Director | Role |
|---|---|
| Peter Harwin | Chairman of the Board |
| Andrew Cheng | Board Director |
| Cameron Turtle | Board Director |
| Chris Cain | Board Director |
| Jennifer Jarrett | President and Chief Executive Officer in March 2026, Board Director |
| Julianne Bruno | Board Director |
| Michael Landsittel | Board Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −4.7% |
| Q2 2026 | Aug 10, 2026 · After close | +2.8% |
| Q1 2026 | May 13, 2026 | +3.4% |
| Q4 2025 | Mar 20, 2026 | +20.1% |
| Q3 2025 | Nov 7, 2025 | +196.4% |
| Q2 2025 | Aug 6, 2025 | −4.1% |
| Q1 2025 | May 9, 2025 | −2.5% |
| Q4 2024 | Mar 19, 2025 · After close | −2.1% |
| Q3 2024 | Nov 1, 2024 · Before open | −1.5% |
| Q2 2024 | Aug 12, 2024 · After close | +6.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 29, 2024 · After close | −3.7% |
| Q4 2023 | Mar 25, 2024 | −3.7% |
| Q3 2023 | Nov 6, 2023 · After close | +7.4% |
| Q2 2023 | Jul 31, 2023 · After close | −9.1% |
| Q1 2023 | Apr 28, 2023 | −4.5% |
| Q4 2022 | Mar 9, 2023 · Before open | −8.1% |
| Q3 2022 | Nov 8, 2022 · Before open | −7.3% |
| Q2 2022 | Jul 29, 2022 · Before open | −3.6% |
| Q1 2022 | Apr 29, 2022 | 0.0% |
| Q4 2021 | Feb 17, 2022 · After close | −5.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 23 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 22 slides | May 2026 |
IPO
Went public as Galecto, Inc. Priced at US$15.00 a share on Oct 28, 2020.
- Price
- US$15.00 a share
- Shares offered
- 5,666,667 shares of common stock
- Offering size
- US$85 million
- Underwriters' option
- Up to 850,000 more shares
- Underwriters
- BofA Securities, SVB Leerink, Kempen & Co, Credit Suisse · In the order on the cover
- Shares delivered
- On or about Nov 2, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 2, 2020 |
| Filed publicly | Oct 7, 2020 |
| Amended once | Oct 22, 2020 |
| Shares registered with an exchange | Oct 23, 2020 |
| Declared effective by the SEC | Oct 28, 2020 |
| Final prospectus, with the price | Oct 30, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 30, 2020 |
| EFFECT · Notice that a registration is effective | Oct 28, 2020 |
| CERT · Exchange's certificate of listing | Oct 28, 2020 |
| CORRESP · Letter to the SEC | Oct 26, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 23, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| S-1/A · Registration statement, amended | Oct 22, 2020 |
| CORRESP · Letter to the SEC | Oct 20, 2020 |
| UPLOAD · Letter from the SEC | Oct 19, 2020 |
All 15 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 13, 2020 |
| CORRESP · Letter to the SEC | Oct 7, 2020 |
| S-1 · Registration statement | Oct 7, 2020 |
| UPLOAD · Letter from the SEC | Sep 29, 2020 |
| DRS · Draft registration statement | Sep 2, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 34.0K | 181.0K | 830.0K | 490.0K | 441.0K | 188.0K | 111.0K | |
| Gross profit | -34.0K | -181.0K | -830.0K | -490.0K | -441.0K | -188.0K | -111.0K | |
| Research and development | 26.9M | 6.40M | 23.8M | 48.2M | 38.5M | 24.6M | 19.7M | 10.1M |
| Selling, general and administrative | 9.69M | 10.5M | 12.7M | 13.0M | 13.7M | |||
| Operating income | -210.9M | -22.3M | -39.9M | -61.2M | -52.2M | -33.6M | 39.0M | -12.9M |
| Depreciation and amortization | 22.0K | 21.0K | 269.0K | 42.0K | 20.0K | 188.0K | 111.0K | |
| EBITDA | -210.8M | -22.2M | -39.6M | -61.2M | -52.2M | -33.4M | 39.1M | |
| Interest expense | 2.97M | |||||||
| Income before tax | -209.8M | -21.4M | -38.3M | -61.6M | -51.8M | -34.8M | -36.5M | -15.9M |
| Income tax | 50.0K | 41.0K | 0 | 0 | 0 | 0 | 0 | |
| Net income | -209.8M | -21.4M | -38.3M | -61.6M | -51.8M | -34.8M | -36.5M | -15.9M |
| Earnings per share, basic | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 | -7.62 | -161.82 | -15.60 |
| Earnings per share, diluted | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 | -7.62 | -161.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 257.6M | 14.2M | 21.5M | 32.8M | 62.6M | 163.6M | 11.3M | 31.0M |
| Short-term investments | 0 | 0 | 11.7M | 27.4M | 37.6M | |||
| Receivables | 899.0K | 881.0K | 1.72M | 1.38M | 2.28M | 2.21M | 41.1M | 989.0K |
| Current assets | 260.4M | 16.8M | 36.8M | 63.9M | 110.1M | 169.3M | 56.1M | 35.0M |
| Property, plant and equipment | 36.0K | 57.0K | 78.0K | 357.0K | 203.0K | |||
| Total assets | 260.5M | 17.1M | 38.2M | 73.2M | 122.2M | 171.6M | 56.6M | 35.1M |
| Accounts payable | 444.0K | 377.0K | 1.70M | 3.35M | 1.53M | 2.85M | 3.33M | 1.41M |
| Current liabilities | 20.1M | 1.20M | 5.83M | 11.1M | 4.54M | 5.57M | 7.93M | 4.44M |
| Total debt | 68.0K | 1.43M | 249.0K | 804.0K | 847.0K | 915.0K | 298.0K | |
| Total liabilities | 20.1M | 1.30M | 5.90M | 11.4M | 4.99M | 6.11M | 8.14M | 4.44M |
| Shareholders' equity | 239.0M | 14.5M | 32.3M | 61.8M | 117.2M | 165.5M | -71.1M | 30.7M |
| Shares outstanding | 1.60M | 1.32M | 1.08M | 25.7M | 25.3M | 25.3M | 260.0K | 1.02M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.73M | -18.6M | -36.9M | -42.9M | -52.3M | -38.2M | -19.3M | -13.7M |
| Capital spending | 0 | 0 | 0 | -196.0K | -223.0K | 0 | 0 | 0 |
| Free cash flow | -6.73M | -18.6M | -36.9M | -43.1M | -52.5M | -38.2M | -19.3M | -13.7M |
| Cash from investing | -17.4M | 11.7M | 22.3M | 12.4M | -48.0M | -326.0K | ||
| Cash from financing | 266.8M | 0 | 2.88M | 507.0K | 0 | 187.4M | 42.9M | |
| Change in cash | 242.7M | -6.97M | -11.7M | -30.0M | -100.4M | 149.2M | -19.7M | 31.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 13, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2026 | Other filings | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| POSASR | Aug 10, 2026 | Other filings | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| S-8 POS | Aug 10, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Aug 10, 2026 | Offer document | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 20, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 8, 2026 | Insider trade | SEC |
| 8-K · Current report | May 4, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | May 1, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 23, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 11, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 10, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Feb 10, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jan 2, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Dec 31, 2025 | Meeting notice | SEC |
| 424B3 · Prospectus | Dec 31, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Dec 16, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Dec 16, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Dec 9, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 5, 2025 | Big-stake notice | SEC |
| D | Nov 21, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Nov 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2025 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 25, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 7, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 1, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 7, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 18, 2024 | Current report | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 29, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 16, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 21, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Apr 29, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 26, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 8, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 8, 2024 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 3, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 2, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2023 | Current report | SEC |
| 8-K · Current report | Sep 26, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 18, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 5, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 30, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 30, 2023 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Aug 21, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 21, 2023 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 17, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 15, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 15, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 2, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 2, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 31, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 31, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 27, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 25, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 25, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 25, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 25, 2023 | Other filings | SEC |
| 4 · Change in ownership | Jul 17, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 17, 2023 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 13, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 13, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 13, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 13, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
This page holds 200 of 353 filings. Open Filings
Cap table
Built by 6ix from Damora Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 61,904,742
- Fully diluted
- 61,904,742
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 61,904,742 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 61,904,742 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Harwin Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past) | Chairman of the Board · Since at least Nov 10, 2025 |
| Jennifer Jarrett Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); Zura Bio Limited (Director · Since at least Mar 20, 2023); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 25, 2018); Arcus Biosciences, Inc. (Chief Operating Officer · Since at least Mar 14, 2018); Radius Health, Inc. (Director · May 18, 2022 – Aug 15, 2022 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Arena Pharmaceuticals Inc (Director · Jun 13, 2017 – Mar 11, 2022 · Past); Audentes Therapeutics Inc (Director · Jun 12, 2017 – Jan 15, 2020 · Past); Medivation Inc (Chief Financial Officer · Apr 7, 2016 – Sep 28, 2016 · Past) | President and Chief Executive Officer in March 2026, Board Director · Since at least Mar 30, 2026 |
| Chau Quang Khuong Other companies: Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 22, 2023 · Past); Inspire Medical Systems, Inc. (Director · May 2, 2018 – Oct 9, 2020 · Past); Synlogic Inc (Director · Aug 28, 2017 – Apr 20, 2021 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Jun 23, 2017 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Oct 25, 2017 · Past); Otonomy Inc (Director · Aug 12, 2014 – Jun 21, 2016 · Past) | Director · Oct 28, 2020 – Jun 14, 2023 · Past |
| Amit Munshi Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Dec 4, 2025); Inhibikase Therapeutics, Inc. (Board of Directors Chair, Inhibikase; Chief Executive Officer of Orna Therapeutics · Since at least Oct 21, 2024); Zura Bio Limited (Chairman · Since at least Mar 20, 2023); Social Capital Suvretta Holdings Corp IV (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Pulmatrix, Inc. (Director · Jun 13, 2017 – Jan 28, 2021 · Past); Arena Pharmaceuticals Inc (President and CEO, Director · May 11, 2016 – Mar 11, 2022 · Past); EPIRUS Biopharmaceuticals Inc (Chief Executive Officer, Director · Jul 15, 2014 – Feb 27, 2016 · Past) | Director · Since at least Oct 28, 2020 |
| Andrew Cheng Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Akero Therapeutics Inc (President and CEO, Director · Since at least Jun 19, 2019); Arbutus Biopharma Corporation (Director · Aug 17, 2019 – Jun 3, 2021 · Past) | Board Director · Since at least Aug 10, 2026 |
| Cameron Turtle Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Spyre Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 22, 2023); BridgeBio Pharma, Inc. (See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past) | Board Director · Since at least Mar 23, 2026 |
| Carl Goldfischer Other companies: Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Zvue Corp (Director · Oct 1, 2008 – Oct 1, 2008 · Past); ReShape Lifesciences Inc (Director · Nov 14, 2007 – May 25, 2017 · Past) | Director · Since at least Oct 28, 2020 |
| Anne Prener Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 25, 2026); Kaleido Biosciences, Inc. (Director · Apr 1, 2020 – Jun 30, 2021 · Past); Rubius Therapeutics Inc (Director · Dec 17, 2019 – May 12, 2022 · Past) | Director · Since at least Jan 8, 2021 |
| Chris Cain Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025); Cogent Biosciences, Inc. (Director · Since at least Jul 6, 2020) | Board Director · Since at least Nov 10, 2025 |
| David Shapiro Other companies: Design Therapeutics, Inc. (Director · Since at least Mar 31, 2026); VivoSim Labs, Inc. (Director · Dec 4, 2018 – Sep 5, 2019 · Past); Intercept Pharmaceuticals Inc (Chief Medical Officer · Oct 10, 2012 – May 1, 2019 · Past) | Director · Since at least Oct 28, 2020 |
All 28 people
| Person | Seat |
|---|---|
| Jayson Donald Alexander Dallas Other companies: Aimmune Therapeutics Inc (President and CEO, Director · Jun 19, 2018 – Oct 10, 2020 · Past); Arena Pharmaceuticals Inc (Director · Feb 13, 2017 – Mar 11, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP & Chief Commercial Officer · Aug 3, 2015 – Jun 1, 2018 · Past) | Director · Since at least Nov 19, 2020 |
| Amy B. Wechsler Other companies: Bausch Health Companies Inc. (Board-Certified Dermatologist & Psychiatrist, Dr. Amy Wechsler Dermatology · Since at least Jun 14, 2016) | Director · Since at least Oct 11, 2024 |
| Becker Hewes Other companies: Blueprint Medicines Corp (Chief Medical Officer · Since at least Jan 11, 2021) | Chief Medical Officer · Since at least Jan 5, 2026 |
| Brian Burkavage Other companies: Passage Bio, Inc. (Controller · May 30, 2021 – May 30, 2021 · Past) | Senior Vice President, Finance · Since at least May 1, 2026 |
| Garrett Winslow Other companies: Spring Bank Pharmaceuticals Inc (General Counsel and Secretary · Mar 5, 2020 – Mar 5, 2020 · Past) | General Counsel · Since at least May 3, 2021 |
| Jonathan Freve Other companies: Spring Bank Pharmaceuticals Inc (CFO & Treasurer · May 5, 2016 – Mar 5, 2020 · Past) | Chief Financial Officer · Oct 28, 2020 – Jan 3, 2024 · Past |
| Julianne Bruno Other companies: CRISPR Therapeutics AG (Chief Operating Officer · May 23, 2024 – Mar 20, 2025 · Past) | Board Director · Since at least Nov 10, 2025 |
| Lori Firmani Other companies: Spring Bank Pharmaceuticals Inc (VP of Finance and Treasurer · Apr 24, 2020 – Apr 24, 2020 · Past) | Chief Financial Officer · Since at least Aug 12, 2024 |
| Michael Landsittel Other companies: Blueprint Medicines Corp (Chief Financial Officer · Since at least Aug 11, 2015) | Board Director · Since at least Mar 23, 2026 |
| Anders Pedersen | Chief Operating Officer · Oct 28, 2020 – Jan 4, 2023 · Past |
| Bertil Lindmark | Chief Medical Officer · Oct 28, 2020 – Jan 4, 2023 · Past |
| Hans T Schambye | Chief Executive Officer, Director · Since at least Oct 28, 2020 |
| Jim Baker | Chief Corporate Affairs Officer · Since at least Oct 5, 2026 |
| Matthew Kronmiller | EVP Strategy and CBO · Oct 7, 2024 – Jan 3, 2025 · Past |
| Sherwin Sattarzadeh | Chief Operating Officer · Since at least Jan 5, 2026 |
| Soren Moller | Director · Oct 28, 2020 – Oct 28, 2020 · Past |
| Stephan Christgau | Director · Oct 28, 2020 – Nov 2, 2020 · Past |
| Stephanie Oestreich | Chief Business Officer · Jan 5, 2022 – Jan 4, 2023 · Past |
Log in to ask 6ix AI your own questions about Damora Therapeutics, Inc.